Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) Return on Sales (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Return on Sales for 2 consecutive years, with 35.72% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales changed N/A to 35.72% in Q3 2025 year-over-year; TTM through Sep 2025 was 35.72%, a N/A change, with the full-year FY2024 number at 4.79%, changed N/A from a year prior.
  • Return on Sales was 35.72% for Q3 2025 at Pyxis Oncology, down from 6.41% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.33% in Q1 2024 to a low of 35.72% in Q3 2025.